ScholarWorks@SUNGKYUNKWAN UNIVERSITY: SHIN, BEOM SOO

Detailed Information

SHIN, BEOM SOO (신범수)

Pharmacy (Pharmacy)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

pharmacokinetics:12||Pharmacokinetics:8||LCMS/MS:6||MS:4||sustained release:3||LCMS:3||bioavailability:3||drugdrug interaction:3||radiosensitizer:2||radiotherapy:2||herbal medicine:2||Tumor targeting:2||safety:2||population pharmacokinetic modeling:2||In vitroin vivo correlation:2||in vitroin vivo correlation:2||carbapenem resistance:2||synergy:2||telacebec:2||outer membrane:2||Bioavailability:2||toxicokinetics:2||Brain distribution:2||Plasma:2||population pharmacokinetics:2||LC–MS/MS:2||mathematical modeling:2||glioblastoma:2||Q203:2||Diclofenac:1||Doxorubicin:1||Drug distribution:1||Dry eye disease:1||Enterobacter cloacae:1||Epigenetics:1||Esomeprazole:1||Estimated daily intakes:1||Extendedrelease formulation:1||Fimasartan:1||GLP1 analogs:1||GLP1 receptor agonists:1||Gastric ulcer:1||Glucagonlike peptide1:1||Gold nanoparticles:1||Gold nanorods:1||Guipi Decoction:1||HPLCMS:1||HPLCMS/MS:1||Human biomonitoring:1||Hyangsayukgunjatang:1||Hybrid nanoparticles:1||Hydroxyproline:1||Hydroxypropyl methylcellulose:1||Hypothalamus:1||In situ singlepass perfusion:1||In vitro–in vivo correlation:1||Intestinal permeability:1||Intraindividual variability:1||Intramuscular injection:1||Ketoprofen:1||Klebsiella pneumoniae:1||Lifitegrast:1||Liposome:1||Liraglutide:1||Lymphatic transport:1||Mesupron:1||Modelbased drug development:1||Modeling and simulation:1||Nanoparticle:1||Nanoparticles:1||Nardostachys jatamansi:1||Ocular tissue:1||Pglycoprotein:1||PD modeling:1||PEG length:1||PK:1||Panduratin A:1||Pharmacodynamics:1||Pharmacokinetic modeling:1||Pharmacokinetic profiles:1||Phase 1 trial:1||Photodynamic therapy:1||Photothermal conversion:1||Physiologically based pharmacokinetic model:1||Population pharmacokinetic model:1||Praline:1||Prodrugs:1||Pseudomonas aeruginosa:1||Radiosensitization:1||Rat:1||Regional absorption:1||Retinoic acid:1||Reverse dosimetry with PBPK model:1||Riboflavin:1||Safety:1||Scenariobased probabilistic estimation:1||Semaglutide:1||Silver nanoparticles:1||Sipjeondaebotang:1||Skin:1||Subacute intraveneous injection:1||Sustainedrelease:1||Tacrolimus:1||Telacebec:1||Tissue distribution:1||Tolerability:1||Toxicokinetics:1||Tuberculosis:1||UV filtering agent:1||Validation:1||[6]gingerol:1||absorption:1||absorption window:1||acyclovir:1||antitumor immunity:1||antituberculosis:1||baclofen:1||benzophenone3:1||betalactams:1||cancer immunotherapy:1||capsaicin:1||carbapenems:1||cassette assay:1||cephalosporins:1||combination therapy:1||critical process parameters:1||design of experiments:1||desoxonarchinol A:1||distribution:1||donepezil:1||dosage regimen:1||doxorubicin:1||drug delivery system:1||dynamic hollowfiber infection model:1||dynamic infection model:1||epiilimaquinone:1||erlotinib:1||floating system:1||gefitinib:1||gemcitabine:1||gimeracil:1||herbdrug interaction:1||hexamethylenetetramine:1||highshear wet granulation:1||human heavy chain ferritin:1||ilimaquinone:1||imipenem:1||intermediate quality attributes:1||intragastric:1||intravenous:1||level A IVIVC:1||lipidbased formulation:1||lixisenatide:1||lung cancer:1||lymphatic transport:1||mechanism based:1||mechanistic:1||metabolism:1||methenamine:1||mixture design:1||molecular design:1||monobactams:1||multiple ascending doses:1||multivariate analysis:1||nafamostat:1||permeability:1||pharmacodynamics:1||phase 1 trial:1||phthalimidoalkanamide:1||piperine:1||polymyxin resistance:1||prediction of in vivo pharmacokinetics:1||preservative:1||prothrombin time:1||quality by design:1||rat:1||rivaroxaban:1||scaleup strategy:1||shikimic acid:1||sildenafil:1||sitedependent dissolution:1||solubility:1||stereoselective pharmacokinetics:1||tobramycin:1||tolerability:1||transdermal absorption:1||tuberculosis:1||type 2 diabetes:1||3D printing:1||verapamil:1||5FU:1||Aceclofenac:1||Acetylcarnitine:1||Acinetobacter baumannii:1||Activated esters:1||Albumin:1||Albumin nanoparticles:1||Antitumor therapy:1||Arginine:1||BPE:1||Baclofen:1||Bawu Decoction:1||Beagle dog:1||Betacarotene:1||Bexarotene:1||COVID19:1||Cancer:1||Chlorin e6:1||Chylomicron:1||Citrulline:1||Coadministration:1||Controlled release formulations:1||Cynomolgus monkey:1||DNA mehyltransferase:1||DNA methyltransferase:1||DNMT inhibitor:1||Design of experiment:1||Di2ethylhexyl phthalate (DEHP):1||

STATISTICS: Total View :5,260,499; Today View :4,052

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE